Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assess the Immunogenicity, Safety, Reactogenicity of 1 Dose of 4 Different Formulations of GSK Biologicals' Meningococcal Conjugate Vaccine (MenACWY) vs 1 Dose of Mencevax™ ACWY in Healthy Subjects Aged 15-19 Yrs

NCT00196963 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00196963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00196963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assess the Immunogenicity, Safety, Reactogenicity of 1 Dose of 4 Different Formulations of GSK Biologicals' Meningococcal Conjugate Vaccine (MenACWY) vs 1 Dose of Mencevax™ ACWY in Healthy Subjects Aged 15-19 Yrs
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2005
Completion date
July 31, 2005
Enrollment
125 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

infections, meningococcal